New Analysis Shows Icosapent Ethyl (Vascepa®) Is Cost Effective and Offers Rare Finding of Better Outcomes at Lower Healthcare Costs When Used to Treat High-Risk Patients with Cardiovascular Disease or Diabetes and Other Risk Factors

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing